Home  |  Contact
Due to maintenance work, this service and ftp://ftp.expasy.org will be unavailable from Tuesday August 23rd 18:00 until Wednesday August 24th 08:00 CEST. Apologies for the inconvenience.

UniProtKB/Swiss-Prot Q9UNQ0: Variant p.Gln141Lys

Broad substrate specificity ATP-binding cassette transporter ABCG2
Gene: ABCG2
Variant information

Variant position:  141
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glutamine (Q) to Lysine (K) at position 141 (Q141K, p.Gln141Lys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (Q) to large size and basic (K)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism:  Genetic variations in ABCG2 define the blood group Junior system (JR) [MIM:614490]. Individuals with Jr(a-) blood group lack the Jr(a) antigen on their red blood cells. These individuals may have anti-Jr(a) antibodies in their serum, which can cause transfusion reactions or hemolytic disease of the fetus or newborn. Although the clinical significance of the Jr(a-) blood group has been controversial, severe fatal hemolytic disease of the newborn has been reported. The Jr(a-) phenotype has a higher frequency in individuals of Asian descent, compared to those of European descent. The Jr(a-) phenotype is inherited as an autosomal recessive trait.Genetic variations in ABCG2 influence the variance in serum uric acid concentrations and define the serum uric acid concentration quantitative trait locus 1 (UAQTL1) [MIM:138900]. Excess serum accumulation of uric acid can lead to the development of gout, a common disorder characterized by tissue deposition of monosodium urate crystals as a consequence of hyperuricemia (PubMed:18834626, PubMed:19506252, PubMed:20368174). -
Additional information on the polymorphism described.

Variant description:  Associated with high serum levels of uric acid and increased risk of gout; results in lower urate transport rates compared to wild-type; decreased protein abundance.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  141
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  655
The length of the canonical sequence.

Location on the sequence:   SGYVVQDDVVMGTLTVRENL  Q FSAALRLATTMTNHEKNERI
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERI

Rhesus macaque                SGYVVQDDVVMGTLTVRENLQFSAALRLPTTMTNHEKNERI

Mouse                         SGYVVQDDVVMGTLTVRENLQFSAALRLPTTMKNHEKNERI

Rat                           SGYVVQDDVVMGTLTVRENLQFSAALRLPKAMKTHEKNERI

Pig                           SGYVVQDDVVMGTLTVRENLQFSAALRLPTTMTNHEKNERI

Bovine                        SGYVVQDDVVMGTLTVRENLQFSAALRLPTTMTSYEKNERI

Slime mold                    VAYVVQGDHHMAPFTVRETFKFSADLQMSEGTSEEEKNARV

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 655 Broad substrate specificity ATP-binding cassette transporter ABCG2
Topological domain 1 – 395 Cytoplasmic
Domain 37 – 286 ABC transporter
Helix 136 – 147


Literature citations

Submission
Yoshikawa M.; Yabuuchi H.; Ikegami Y.; Ishikawa T.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANT LYS-141;

Submission
SeattleSNPs variation discovery resource;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS MET-12; LYS-141; HIS-296 AND THR-528;

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2); VARIANT LYS-141;

Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
Woodward O.M.; Kottgen A.; Coresh J.; Boerwinkle E.; Guggino W.B.; Kottgen M.;
Proc. Natl. Acad. Sci. U.S.A. 106:10338-10342(2009)
Cited for: POLYMORPHISM; INVOLVEMENT IN UAQTL1; ASSOCIATION OF VARIANT LYS-141 WITH GOUT; CHARACTERIZATION OF VARIANT LYS-141; FUNCTION; CATALYTIC ACTIVITY; SUBCELLULAR LOCATION;

Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.
Matsuo H.; Takada T.; Ichida K.; Nakamura T.; Nakayama A.; Ikebuchi Y.; Ito K.; Kusanagi Y.; Chiba T.; Tadokoro S.; Takada Y.; Oikawa Y.; Inoue H.; Suzuki K.; Okada R.; Nishiyama J.; Domoto H.; Watanabe S.; Fujita M.; Morimoto Y.; Naito M.; Nishio K.; Hishida A.; Wakai K.; Asai Y.; Niwa K.; Kamakura K.; Nonoyama S.; Sakurai Y.; Hosoya T.; Kanai Y.; Suzuki H.; Hamajima N.; Shinomiya N.;
Sci. Transl. Med. 1:5RA11-5RA11(2009)
Cited for: FUNCTION; CATALYTIC ACTIVITY; POLYMORPHISM; INVOLVEMENT IN UAQTL1; ASSOCIATION OF VARIANT LYS-141 WITH GOUT;

Cellular expression and function of naturally occurring variants of the human ABCG2 multidrug transporter.
Zambo B.; Mozner O.; Bartos Z.; Toeroek G.; Varady G.; Telbisz A.; Homolya L.; Orban T.I.; Sarkadi B.;
Cell. Mol. Life Sci. 77:365-378(2020)
Cited for: FUNCTION; CATALYTIC ACTIVITY; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANT LYS-141; TRP-147; MET-153; LYS-360 DEL; CYS-373; MET-434 AND PRO-476; MUTAGENESIS OF MET-71; LYS-86 AND ARG-383;

Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8.
Iida A.; Saito S.; Sekine A.; Mishima C.; Kitamura Y.; Kondo K.; Harigae S.; Osawa S.; Nakamura Y.;
J. Hum. Genet. 47:285-310(2002)
Cited for: VARIANTS MET-12 AND LYS-141;

Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.
Zamber C.P.; Lamba J.K.; Yasuda K.; Farnum J.; Thummel K.; Schuetz J.D.; Schuetz E.G.;
Pharmacogenetics 13:19-28(2003)
Cited for: VARIANTS MET-12; LYS-141; LEU-206 AND TYR-590;

Single nucleotide polymorphisms modify the transporter activity of ABCG2.
Morisaki K.; Robey R.W.; Oezvegy-Laczka C.; Honjo Y.; Polgar O.; Steadman K.; Sarkadi B.; Bates S.E.;
Cancer Chemother. Pharmacol. 56:161-172(2005)
Cited for: CHARACTERIZATION OF VARIANTS MET-12; LYS-141 AND ASN-620;

Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.
Maekawa K.; Itoda M.; Sai K.; Saito Y.; Kaniwa N.; Shirao K.; Hamaguchi T.; Kunitoh H.; Yamamoto N.; Tamura T.; Minami H.; Kubota K.; Ohtsu A.; Yoshida T.; Saijo N.; Kamatani N.; Ozawa S.; Sawada J.;
Drug Metab. Pharmacokinet. 21:109-121(2006)
Cited for: VARIANTS MET-12; LEU-13; LYS-141; GLN-160; ARG-354; LEU-431; ASN-441 AND LEU-489;

Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort.
Toyoda Y.; Mancikova A.; Krylov V.; Morimoto K.; Pavelcova K.; Bohata J.; Pavelka K.; Pavlikova M.; Suzuki H.; Matsuo H.; Takada T.; Stiburkova B.;
Cells 8:0-0(2019)
Cited for: VARIANTS TRP-147; MET-153; LYS-360 DEL; CYS-373; ALA-421; MET-434; PRO-476; ARG-572 AND ASN-620; CHARACTERIZATION OF VARIANTS LYS-141; TRP-147; MET-153; LYS-360 DEL; CYS-373; ALA-421; MET-434; PRO-476; ARG-572 AND ASN-620; FUNCTION; CATALYTIC ACTIVITY; SUBCELLULAR LOCATION;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.